ADMA Biologics News - November 2026
🟢 ADMA Biologics is trading 25% up after raising full-year adjusted earnings outlook
ADMA Biologics is trading at $13.09 (+24.90%) on November 5 after reporting third-quarter results and raising its full-year adjusted earnings outlook. -...
🟢 ADMA Biologics is trading 22.23% up in pre-market after stronger third-quarter results and raised profit outlook
ADMA Biologics is trading at $12.81, up 22.23% in pre-market on November 5 after its third-quarter report, released after the November 4 close, raised minimum...
ADMA Biologics Surges 27% on a Blowout Quarter — But Can Its Star Drug Carry the Whole Company?
Shares vaulted 27.5% after hours as ADMA Biologics reported third-quarter results that snapped a streak of disappointments, raising an urgent question: whether...
🟢 ADMA Biologics is trading 27.48% up in after-hours trading after Q3 revenue beat
ADMA Biologics is trading at $13.36, up 27.48%, in after-hours trading after Q3 revenue beat expectations. - The price followed the November 4, 2026...
ADMA Biologics third quarter 2026 revenue of $141M beat estimates behind 31% Asceniv growth
ADMA Biologics reported total revenue of $141.1 million for the third quarter 2026, surpassing analyst expectations of $139.8 million. The results were driven...
ADMA Biologics Inc Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
ADMA Biologics is expected to report Q3 2026 consensus revenue of $139.8 million (+4.16% YoY) and EPS of $0.19 (+18.75% YoY), with its stock currently trading...